MiniMed Taps Incyte GC Sheila Denton as New General Counsel…

Event summary

Sheila Denton joins MiniMed as General Counsel & Corporate Secretary effective September 28, 2026.
Denton brings 25+ years of experience in global pharmaceutical and biotech companies, including roles at Incyte and Boehringer Ingelheim.
She succeeds Courtney Nelson Wills, who departed to pursue new professional opportunities.
MiniMed operates in 80 countries, offering a full-stack diabetes technology ecosystem.

The big picture

MiniMed's appointment of Sheila Denton underscores its focus on scaling as an independent public company. Denton's background in corporate governance and strategic transactions aligns with MiniMed's mission to advance diabetes technology globally. Her experience at Incyte and Boehringer Ingelheim suggests a strategic emphasis on regulatory compliance and high-stakes transactions, critical for MiniMed's continued expansion in the competitive healthcare sector.

What we're watching

Strategic Transactions: Whether Denton's experience in strategic transactions will accelerate MiniMed's growth initiatives.
Regulatory Compliance: How Denton's regulatory expertise will navigate MiniMed through evolving healthcare regulations.
Team Performance: The pace at which Denton can build and lead high-performing global teams at MiniMed.